Dendreon Co. (DNDN), Baker Hughes (BHI), HollyFrontier Corp (HFC), Weyerhaeuser (WY), Excel Maritime Carriers Ltd (EXM) and Parker Drilling Company (PKD) had ratings and price targets on them adjusted by analysts.
Wells Fargo & Co. downgraded Baker Hughes (BHI) from a "Outperform" rating to an "Market Perform" rating.
Raymond James downgraded HollyFrontier Corp (HFC) from a "Outperform" rating to an "Underperform" rating.
Scotia Capital downgraded Weyerhaeuser (WY) from a "Sector Perform" rating to an "Underperform" rating.
Canaccord Genuity initiated coverage on Dendreon Co. (DNDN). They placed a "Hold" rating and a price target of $11.00 on the company.
Imperial Capital initiated coverage on Excel Maritime Carriers Ltd (EXM). They placed an "Underperform" rating and price target of $1.14 on the company.
Sidoti initiated coverage on Parker Drilling Company (PKD). They placed a "Buy" rating on the company.
Showing posts with label Dendreon. Show all posts
Showing posts with label Dendreon. Show all posts
Monday, March 26, 2012
Thursday, March 15, 2012
Dendreon (DNDN) (RRMS) (EXEL) (PGN) (NUVA) (OMG) (PFCB) Ratings, Price Targets
Dendreon Co. (DNDN), Rose Rock Midstream (RRMS), Exelixis, Inc. (EXEL), Progress Energy (PGN), NuVasive (NUVA), OM Group Inc (OMG) and P.F. Chang's China Bistro (PFCB) had ratings and price targets on them adjusted by analysts.
Robert W. Baird upgraded Rose Rock Midstream (RRMS) to an "Outperform" rating.
Stifel Nicolaus initiated coverage on Dendreon Co. (DNDN). They placed a "Hold" rating on the company.
Stifel Nicolaus initiated coverage on Exelixis, Inc. (EXEL). They placed a "Buy" rating and a price target of $8.00 on the company.
Dahlman Rose initiated coverage on Progress Energy (PGN). They placed a "Hold" rating on the company.
JMP Securities upgraded NuVasive (NUVA) from a "Market Perform" rating to a "Outperform" rating.
First Analysis upgraded OM Group Inc (OMG) from a "Equal Weight" rating to a "Overweight" rating.
Argus upgraded P.F. Chang's China Bistro (PFCB) from a "Sell" rating to a "Hold" rating.
Robert W. Baird upgraded Rose Rock Midstream (RRMS) to an "Outperform" rating.
Stifel Nicolaus initiated coverage on Dendreon Co. (DNDN). They placed a "Hold" rating on the company.
Stifel Nicolaus initiated coverage on Exelixis, Inc. (EXEL). They placed a "Buy" rating and a price target of $8.00 on the company.
Dahlman Rose initiated coverage on Progress Energy (PGN). They placed a "Hold" rating on the company.
JMP Securities upgraded NuVasive (NUVA) from a "Market Perform" rating to a "Outperform" rating.
First Analysis upgraded OM Group Inc (OMG) from a "Equal Weight" rating to a "Overweight" rating.
Argus upgraded P.F. Chang's China Bistro (PFCB) from a "Sell" rating to a "Hold" rating.
Friday, January 6, 2012
FedEx (FDX) (DNDN) (EXC) (CCL) (BAX) (ESV) Ratings, Price Targets
FedEx (NYSE: FDX), Dendreon Co. (NASDAQ: DNDN), Exelon Co. (NYSE: EXC), Carnival Co. (NYSE: CCL), Baxter International Inc. (NYSE: BAX) and ENSCO PLC (NYSE: ESV) ratings and price targets.
Dendreon Co. (DNDN) had its “Neutral” rating reiterated by Goldman Sachs (NYSE:GS).
Exelon Co. (EXC) was downgraded by Macquarie from an “Outperform” rating to a “Neutral” rating.
Carnival Co. (CCL) had its “Neutral” rating reiterated by Zacks Investment Research. They have a price target of $35.00 on the company.
Baxter International Inc. (BAX) is now covered by Dougherty & Co. They have a “Neutral” rating on the company.
ENSCO PLC (ESV) is now covered by Global Hunter Securities. They have a “Buy” rating on the company.
FedEx (FDX) is now covered by Wells Fargo & Co. (NYSE:WFC). They have an “Outperform” rating on the company.
Dendreon Co. (DNDN) had its “Neutral” rating reiterated by Goldman Sachs (NYSE:GS).
Exelon Co. (EXC) was downgraded by Macquarie from an “Outperform” rating to a “Neutral” rating.
Carnival Co. (CCL) had its “Neutral” rating reiterated by Zacks Investment Research. They have a price target of $35.00 on the company.
Baxter International Inc. (BAX) is now covered by Dougherty & Co. They have a “Neutral” rating on the company.
ENSCO PLC (ESV) is now covered by Global Hunter Securities. They have a “Buy” rating on the company.
FedEx (FDX) is now covered by Wells Fargo & Co. (NYSE:WFC). They have an “Outperform” rating on the company.
Wednesday, December 7, 2011
Dendreon (DNDN) (DRI) (DVN) (ECTE) (GLW) Ratings Reiterated
Dendreon Co. (NASDAQ: DNDN), Darden Restaurants, Inc. (NYSE: DRI), Devon Energy Co. (NYSE: DVN), Echo Therapeutics (NASDAQ: ECTE) and Corning Inc. (NYSE: GLW) had ratings on them reiterated by analysts.
Robert W. Baird reiterated its "Neutral" rating on Dendreon Co. (DNDN).
Wells Fargo & Co. (NYSE:WFC) reiterated its "Outperform" rating on Darden Restaurants, Inc. (DRI).
Jefferies (NYSE:JEF) reiterated its "Buy" rating on Devon Energy Co. (DVN). They have a price target of $90.00 on the company.
LifeTech Capital reiterated its "Strong Buy" rating on Echo Therapeutics (ECTE). They have a price target of $6.00 on the company.
Barclays Capital (NYSE:BCS) reiterated its "Overweight" rating on Corning Inc. (GLW).
Robert W. Baird reiterated its "Neutral" rating on Dendreon Co. (DNDN).
Wells Fargo & Co. (NYSE:WFC) reiterated its "Outperform" rating on Darden Restaurants, Inc. (DRI).
Jefferies (NYSE:JEF) reiterated its "Buy" rating on Devon Energy Co. (DVN). They have a price target of $90.00 on the company.
LifeTech Capital reiterated its "Strong Buy" rating on Echo Therapeutics (ECTE). They have a price target of $6.00 on the company.
Barclays Capital (NYSE:BCS) reiterated its "Overweight" rating on Corning Inc. (GLW).
Monday, November 14, 2011
Dendreon (DNDN) (ALGT) (AMCX) (TTWO) (CAJ) (CIM) (EW) Upgraded
Dendreon Co. (NASDAQ: DNDN), Allegiant Travel (NASDAQ: ALGT), AMC Networks (NASDAQ: AMCX), Take-Two (NASDAQ: TTWO), Canon (NYSE: CAJ), Chimera Investment Co. (NYSE: CIM) and Edwards Lifesciences (NYSE: EW) were upgraded by analysts.
Dendreon Co. (DNDN) was upgraded by Sanford C. Bernstein from an “Underperform” rating to a “Market Perform” rating.
Allegiant Travel (ALGT) was upgraded by Ticonderoga from a “Neutral” rating to a “Buy” rating. They have a price target of $60.00 on the company.
AMC Networks (AMCX) was upgraded by Stifel Nicolaus from a “Sell” rating to a “Hold” rating.
Take-Two (TTWO) was upgraded by Hilliard Lyons from a “Long” rating to a “Term Buy” rating. They have a price target of $18.00 on the company.
Canon (CAJ) was upgraded by Credit Suisse (NYSE:CS) from a “Neutral” rating to an “Outperform” rating.
Chimera Investment Co. (CIM) was upgraded by Sterne Agee from an “Underperform” rating to a “Neutral” rating.
Edwards Lifesciences (EW) was upgraded by Lazard Capital from a “Neutral” rating to a “Buy” rating.
Dendreon Co. (DNDN) was upgraded by Sanford C. Bernstein from an “Underperform” rating to a “Market Perform” rating.
Allegiant Travel (ALGT) was upgraded by Ticonderoga from a “Neutral” rating to a “Buy” rating. They have a price target of $60.00 on the company.
AMC Networks (AMCX) was upgraded by Stifel Nicolaus from a “Sell” rating to a “Hold” rating.
Take-Two (TTWO) was upgraded by Hilliard Lyons from a “Long” rating to a “Term Buy” rating. They have a price target of $18.00 on the company.
Canon (CAJ) was upgraded by Credit Suisse (NYSE:CS) from a “Neutral” rating to an “Outperform” rating.
Chimera Investment Co. (CIM) was upgraded by Sterne Agee from an “Underperform” rating to a “Neutral” rating.
Edwards Lifesciences (EW) was upgraded by Lazard Capital from a “Neutral” rating to a “Buy” rating.
Friday, August 5, 2011
Tiffany (TIF) (BKI) (DNDN) (DVA) (FICO) Upgraded
Tiffany & Co. (NYSE: TIF), Buckeye Technologies Inc. (NYSE: BKI), Dendreon Co. (NASDAQ: DNDN), DaVita Inc. (NYSE: DVA) and FICO (NASDAQ: FICO) upgraded by analysts.
Tiffany & Co. (TIF) was upgraded by Goldman Sachs (NYSE:GS) from a “Sell” rating to a “Neutral” rating. They have a price target of $68.00 on the company.
Buckeye Technologies Inc. (BKI) was upgraded by UBS AG (NYSE:UBS) from a “Neutral” rating to a “Buy” rating. They have a price target of $30.00 on the company, up from $28.00.
Dendreon Co. (DNDN) was upgraded by Credit Suisse (NYSE:CS) from an “Underperform” rating to a “Neutral” rating. They have a price target of $22.00 on the company.
DaVita Inc. (DVA) was upgraded by Raymond James (NYSE:JRF) from a “Market Perform” rating to an “Outperform” rating. They have a price target of $93.00 on the company.
FICO (FICO) was upgraded by Keefe, Bruyette & Woods, Inc from an “Underperform” rating to a “Market Perform” rating.
Tiffany & Co. (TIF) was upgraded by Goldman Sachs (NYSE:GS) from a “Sell” rating to a “Neutral” rating. They have a price target of $68.00 on the company.
Buckeye Technologies Inc. (BKI) was upgraded by UBS AG (NYSE:UBS) from a “Neutral” rating to a “Buy” rating. They have a price target of $30.00 on the company, up from $28.00.
Dendreon Co. (DNDN) was upgraded by Credit Suisse (NYSE:CS) from an “Underperform” rating to a “Neutral” rating. They have a price target of $22.00 on the company.
DaVita Inc. (DVA) was upgraded by Raymond James (NYSE:JRF) from a “Market Perform” rating to an “Outperform” rating. They have a price target of $93.00 on the company.
FICO (FICO) was upgraded by Keefe, Bruyette & Woods, Inc from an “Underperform” rating to a “Market Perform” rating.
Clorox (CLX) (AGN) (BAH) (DNDN) (ENTR) Downgraded
Clorox Co. (NYSE: CLX), Allergan, Inc. (NYSE: AGN), Booz Allen Hamilton Holding Co. (NYSE: BAH), Dendreon Co. (NASDAQ: DNDN) and Entropic Communications (NASDAQ: ENTR) downgraded by analysts.
Allergan, Inc. (AGN) was downgraded by Piper Jaffray (NYSE:PJC) from an “Overweight” rating to a “Neutral” rating. They have a price target of $89.00 on the company.
Booz Allen Hamilton Holding Co. (BAH) was downgraded by Wells Fargo & Co. (NYSE:WFC) to an “Underweight” rating.
Clorox Co. (CLX) was downgraded by Caris & Company from an “Average” rating to a “Below Average” rating. They have a price target of $60.00 on the company.
Dendreon Co. (DNDN) was downgraded by Brean Murray from a “Buy” rating to a “Sell” rating. They have a price target of $6.00 on the company, down from $60.00.
Entropic Communications (ENTR) was downgraded by JPMorgan Chase & Co. (NYSE:JPM) from an “Overweight” rating to a “Neutral” rating.
Allergan, Inc. (AGN) was downgraded by Piper Jaffray (NYSE:PJC) from an “Overweight” rating to a “Neutral” rating. They have a price target of $89.00 on the company.
Booz Allen Hamilton Holding Co. (BAH) was downgraded by Wells Fargo & Co. (NYSE:WFC) to an “Underweight” rating.
Clorox Co. (CLX) was downgraded by Caris & Company from an “Average” rating to a “Below Average” rating. They have a price target of $60.00 on the company.
Dendreon Co. (DNDN) was downgraded by Brean Murray from a “Buy” rating to a “Sell” rating. They have a price target of $6.00 on the company, down from $60.00.
Entropic Communications (ENTR) was downgraded by JPMorgan Chase & Co. (NYSE:JPM) from an “Overweight” rating to a “Neutral” rating.
Dendreon (DNDN) (WLT) (WFR) (OSG) (LAMR) (EE) Downgraded
Dendreon Co. (NASDAQ: DNDN), Walter Energy (NYSE: WLT), MEMC Electronic Materials Inc (NYSE: WFR), Overseas Shipholding Group Inc. (NYSE: OSG), Lamar Advertising Company (NASDAQ: LAMR) and El Paso Electric (NYSE: EE) downgraded by analysts.
Dendreon Co. (DNDN) was downgraded by Robert W. Baird from an “Outperform” rating to a “Neutral” rating. They have a price target of $20.00 on the company, down from $56.00.
Walter Energy (WLT) was downgraded by Brean Murray from a “Buy” rating to a “Hold” rating.
MEMC Electronic Materials Inc. (WFR) was downgraded by Ardour Capital from a “Buy” rating to an “Accumulate” rating. They have a price target of $8.50 on the company, down from $16.00.
Overseas Shipholding Group Inc. (OSG) was downgraded by Sterne Agee from a “Neutral” rating to a “Sell” rating. They have a price target of $13.00 on the company, down from $31.00.
Lamar Advertising Company (LAMR) was downgraded by The Benchmark Company from a “Buy” rating to a “Hold” rating. They have a price target of $24.00 on the company, down from $33.00.
El Paso Electric (EE) was downgraded by Ticonderoga from a “Buy” rating to a “Neutral” rating.
Dendreon Co. (DNDN) was downgraded by Robert W. Baird from an “Outperform” rating to a “Neutral” rating. They have a price target of $20.00 on the company, down from $56.00.
Walter Energy (WLT) was downgraded by Brean Murray from a “Buy” rating to a “Hold” rating.
MEMC Electronic Materials Inc. (WFR) was downgraded by Ardour Capital from a “Buy” rating to an “Accumulate” rating. They have a price target of $8.50 on the company, down from $16.00.
Overseas Shipholding Group Inc. (OSG) was downgraded by Sterne Agee from a “Neutral” rating to a “Sell” rating. They have a price target of $13.00 on the company, down from $31.00.
Lamar Advertising Company (LAMR) was downgraded by The Benchmark Company from a “Buy” rating to a “Hold” rating. They have a price target of $24.00 on the company, down from $33.00.
El Paso Electric (EE) was downgraded by Ticonderoga from a “Buy” rating to a “Neutral” rating.
Tuesday, July 19, 2011
Amgen (AMGN) (ASH), (AWK) (CHKP) (DNDN) (EPD) Ratings Reiterated
Amgen, Inc. (NASDAQ: AMGN), Ashland Inc. (NYSE: ASH), American Water Works Co Inc (NYSE: AWK), Check Point Software ((NASDAQ: CHKP), Dendreon Co. (NASDAQ: DNDN), Enterprise Products Partners (NYSE: EPD) ratings reiterated by analysts.
Amgen, Inc. (AMGN) rating reiterated an “overweight” by at Piper Jaffray.
Ashland Inc. (ASH) rating reiterated a “neutral” by JPMorgan Chase & Co. (NYSE:JPM).
American Water Works Co Inc (AWK) rating reiterated a “neutral” by Ladenburg Thalmann.
Check Point Software (CHKP) rating reiterated an “outperform” by Oppenheimer.
Dendreon (DNDN) rating reiterated a “hold” by Citigroup (NYSE:C). They have a price target of $36.00 on the company.
Enterprise Products Partners (EPD) rating reiterated a “buy” by Wunderlich. They have a price target of $48.00 on the company.
Amgen, Inc. (AMGN) rating reiterated an “overweight” by at Piper Jaffray.
Ashland Inc. (ASH) rating reiterated a “neutral” by JPMorgan Chase & Co. (NYSE:JPM).
American Water Works Co Inc (AWK) rating reiterated a “neutral” by Ladenburg Thalmann.
Check Point Software (CHKP) rating reiterated an “outperform” by Oppenheimer.
Dendreon (DNDN) rating reiterated a “hold” by Citigroup (NYSE:C). They have a price target of $36.00 on the company.
Enterprise Products Partners (EPD) rating reiterated a “buy” by Wunderlich. They have a price target of $48.00 on the company.
Tuesday, May 3, 2011
Price Targets on (CPO) (CRK) (DE) (DISH) (DNDN) Updated
Price targets on Corn Products International, Inc. (NYSE: CPO), Comstock Resources Inc (NYSE: CRK), Deere & Company (NYSE: DE), DISH (NASDAQ: DISH) and Dendreon Co. (NASDAQ: DNDN) were updated today by analysts.
Citigroup (NYSE:C) raised their price target on Corn Products International, Inc. (CPO) from $60.00 to $70.00. They have a “buy” rating on the company.
Howard Weil raised their price target on Comstock Resources Inc (CRK) from $31.00 to $37.00. They have an “outperform” rating on the company.
Goldman Sachs (NYSE:GS) raised their price target on Deere & Company (DE) to $109.00. They have a “neutral” rating on the company.
RBC Capital raised their price target on DISH (DISH) from $30.00 to $35.00. They have an “outperform” rating on the company.
Brean Murray cut their price target on Dendreon Co. (DNDN) from $65.00 to $60.00. They have a “buy” rating on the company.
Citigroup (NYSE:C) raised their price target on Corn Products International, Inc. (CPO) from $60.00 to $70.00. They have a “buy” rating on the company.
Howard Weil raised their price target on Comstock Resources Inc (CRK) from $31.00 to $37.00. They have an “outperform” rating on the company.
Goldman Sachs (NYSE:GS) raised their price target on Deere & Company (DE) to $109.00. They have a “neutral” rating on the company.
RBC Capital raised their price target on DISH (DISH) from $30.00 to $35.00. They have an “outperform” rating on the company.
Brean Murray cut their price target on Dendreon Co. (DNDN) from $65.00 to $60.00. They have a “buy” rating on the company.
Monday, May 2, 2011
Coverage on (DNDN) (DTLK) (EXEL) (HSNI) (JDSU) and (MERC) Initiated
Coverage on Dendreon Co. (NASDAQ: DNDN), Datalink Corporation (NASDAQ: DTLK), Exelixis, Inc. (NASDAQ: EXEL), HSN, Inc. (NASDAQ: HSNI), JDS Uniphase Co. (NASDAQ: JDSU) and Mercer International Inc. (NASDAQ: MERC) initiated by analysts.
Credit Suisse (NYSE:CS) initiated coverage on Dendreon Co. (DNDN). They placed an “underperform” rating on the company.
Canaccord Genuity initiated coverage on Datalink Corporation (DTLK). They placed a “buy” rating and a price target of $10.00 on the company.
Goldman Sachs (NYSE:GS) initiated coverage on Exelixis, Inc. (EXEL). They placed a “neutral” rating and a price target of $13.00 on the company.
Piper Jaffray (NYSE:PJF) initiated coverage on HSN, Inc. (HSNI). They placed an “overweight” rating and a price target of $45.00 on the company.
Pacific Crest initiated coverage on JDS Uniphase Co. (JDSU). They placed an “outperform” rating on the company.
Canaccord Genuity initiated coverage on Mercer International Inc. (MERC). They placed a “buy” rating on the company.
Credit Suisse (NYSE:CS) initiated coverage on Dendreon Co. (DNDN). They placed an “underperform” rating on the company.
Canaccord Genuity initiated coverage on Datalink Corporation (DTLK). They placed a “buy” rating and a price target of $10.00 on the company.
Goldman Sachs (NYSE:GS) initiated coverage on Exelixis, Inc. (EXEL). They placed a “neutral” rating and a price target of $13.00 on the company.
Piper Jaffray (NYSE:PJF) initiated coverage on HSN, Inc. (HSNI). They placed an “overweight” rating and a price target of $45.00 on the company.
Pacific Crest initiated coverage on JDS Uniphase Co. (JDSU). They placed an “outperform” rating on the company.
Canaccord Genuity initiated coverage on Mercer International Inc. (MERC). They placed a “buy” rating on the company.
Ratings on (DNDN) (DO) (ESV) (INFA) Initiated by Analysts
Dendreon Co. (NASDAQ: DNDN), Diamond Offshore Drilling, Inc. (NYSE: DO), ENSCO PLC (NYSE: ESV) and Informatica Co. (NASDAQ: INFA) get ratings initiations from analysts.
ThinkEquity initiated coverage on Dendreon Co. (DNDN). They placed a “buy” rating and a price target of $50.00 on the company.
Canaccord Genuity initiated coverage on Diamond Offshore Drilling, Inc. (DO). They set a “hold” rating and a $88.00 price target on the company.
Canaccord Genuity analysts initiated coverage on shares of ENSCO PLC (ESV). They set a “buy” rating on the company.
UBS AG (NYSE:UBS) analysts initiated coverage on shares of Informatica Co. (INFA). They set a “buy” rating on the company.
ThinkEquity initiated coverage on Dendreon Co. (DNDN). They placed a “buy” rating and a price target of $50.00 on the company.
Canaccord Genuity initiated coverage on Diamond Offshore Drilling, Inc. (DO). They set a “hold” rating and a $88.00 price target on the company.
Canaccord Genuity analysts initiated coverage on shares of ENSCO PLC (ESV). They set a “buy” rating on the company.
UBS AG (NYSE:UBS) analysts initiated coverage on shares of Informatica Co. (INFA). They set a “buy” rating on the company.
Tuesday, February 1, 2011
Alexion (NASDAQ:ALXN), Cadence (NASDAQ:CADX), Cubist (NASDAQ:CBST), Dendreon (NASDAQ:DNDN), Human Genome (NASDAQ:HGSI) Could be Takeover Targets
With time and costs a major factor in the drug industry, companies appear to be hunting for takeover targets like Alexion (NASDAQ:ALXN), Cadence (NASDAQ:CADX), Cubist (NASDAQ:CBST), Dendreon (NASDAQ:DNDN) and Human Genome (NASDAQ:HGSI), which have a pipeline, or are close to developing a pipeline, with soon-to-be-approved drugs.
Others noted in a recent Barron's article as possible takeover candidates were Acorda (NASDAQ:ACOR), AMAG Pharmaceuticals (NASDAQ:AMAG), BioMarin (NASDAQ:BMRN), Cephalon (NASDAQ:CEPH), Jazz Pharma (NASDAQ:JAZZ), Onyx (NASDAQ:ONXX), United Therapeutics (NASDAQ:UTHR), and Salix Pharmaceuticals (NASDAQ:SLXP).
Some of the companies rose on the assertions, with Cadence closing Monday at $7.76, gaining $0.47, or 6.52 percent.
Others noted in a recent Barron's article as possible takeover candidates were Acorda (NASDAQ:ACOR), AMAG Pharmaceuticals (NASDAQ:AMAG), BioMarin (NASDAQ:BMRN), Cephalon (NASDAQ:CEPH), Jazz Pharma (NASDAQ:JAZZ), Onyx (NASDAQ:ONXX), United Therapeutics (NASDAQ:UTHR), and Salix Pharmaceuticals (NASDAQ:SLXP).
Some of the companies rose on the assertions, with Cadence closing Monday at $7.76, gaining $0.47, or 6.52 percent.
Monday, January 10, 2011
Dendreon (NASDAQ:DNDN) Should Meet Guidance Says Deutsche (NYSE:DB)
Based on guidance for Provenge by Dendreon (NASDAQ:DNDN), Deutsche Bank (NYSE:DB) raised their price target on the company, as checks confirms it.
Deutsche Bank said "despite some skepticism about Provenge market opportunity among individual centers, if we calculate the 2011 exit run rate based on our feedback from low, mid, and high-prescribing centers, we estimate on avg centers will treat -5.5 patients /mo. Assuming -100+ centers are up in next 12 months, this implies a $760M annual run rate, in line with guidance."
Guidance for 2011 from Dendreon was for $350 million to $400 million. It also appears there won't be a demand from the EMA for an additional ph 3 trial in order to gain approval.
Deutsche Bank maintains their "Buy" rating on Dendreon, which closed Friday at $38.20, up $2.78, or 7.85 percent. Deutsche raised their price target on them from $44 to $54.
Deutsche Bank said "despite some skepticism about Provenge market opportunity among individual centers, if we calculate the 2011 exit run rate based on our feedback from low, mid, and high-prescribing centers, we estimate on avg centers will treat -5.5 patients /mo. Assuming -100+ centers are up in next 12 months, this implies a $760M annual run rate, in line with guidance."
Guidance for 2011 from Dendreon was for $350 million to $400 million. It also appears there won't be a demand from the EMA for an additional ph 3 trial in order to gain approval.
Deutsche Bank maintains their "Buy" rating on Dendreon, which closed Friday at $38.20, up $2.78, or 7.85 percent. Deutsche raised their price target on them from $44 to $54.
Thursday, January 6, 2011
Dendreon's (NASDAQ:DNDN) PROVENGE Should Receive Positive Rating
With manufacturing capacity issues expected to be resolved soon, and PROVENGE looking positive, Needham sees Dendreon (NASDAQ:DNDN) as a stock of interest in 2011.
Needham said, "We view DNDN as a stock of added interest in 2011. We believe the manufacturing-capacity constraints will be well addressed, and by the end of 2011, we expect all three manufacturing facilities will be on-line with ~10x the current capacity. We are encouraged to see PROVENGE demand remains strong despite limited marketing efforts to date, and physician-prescribing behavior does not seem to be affected by reimbursement concerns. Given the positive MEDCAC panel, we anticipate a positive memo from MEDCAC in March 2011 and a positive ruling in June 2011 regarding payment for on-label PROVENGE use under the National Coverage Analysis. We believe the significant clinical benefits of PROVENGE with 4.1 months improvement in overall survival will likely weigh heavily on the final decision."
Needham & Company reiterates a "Buy" rating on Dendreon, which closed Wednesday at $35.21, down $0.28, or 0.79 percent. They have a price target of $62 on Dendreon.
Needham said, "We view DNDN as a stock of added interest in 2011. We believe the manufacturing-capacity constraints will be well addressed, and by the end of 2011, we expect all three manufacturing facilities will be on-line with ~10x the current capacity. We are encouraged to see PROVENGE demand remains strong despite limited marketing efforts to date, and physician-prescribing behavior does not seem to be affected by reimbursement concerns. Given the positive MEDCAC panel, we anticipate a positive memo from MEDCAC in March 2011 and a positive ruling in June 2011 regarding payment for on-label PROVENGE use under the National Coverage Analysis. We believe the significant clinical benefits of PROVENGE with 4.1 months improvement in overall survival will likely weigh heavily on the final decision."
Needham & Company reiterates a "Buy" rating on Dendreon, which closed Wednesday at $35.21, down $0.28, or 0.79 percent. They have a price target of $62 on Dendreon.
Wednesday, December 15, 2010
Amarin (Nasdaq:AMRN), Amicus (Nasdaq:FOLD), Dendreon (Nasdaq:DNDN), NPS (Nasdaq:NPSP), Orexigen (Nasdaq:OREX), Pharmasset (Nasdaq:VRUS), Best Biotech Ideas for 2011
Within the small and mid-cap biotech sector, Canaccord Genuity named its best ideas for 2011, which include Amarin (Nasdaq:AMRN), Amicus (Nasdaq:FOLD), Dendreon (Nasdaq:DNDN), NPS Pharmaceuticals (Nasdaq:NPSP), Orexigen (Nasdaq:OREX), Pharmasset (Nasdaq:VRUS) and NPS Pharmaceuticals (Nasdaq:NPSP).
Canaccord said, "We believe that small and mid-cap biotech stock performance will continue to be driven by key catalysts: late-stage clinical data, FDA decisions, and sales growth. In addition to profiling each of our Best Ideas, we are providing quick updates on many of our coverage companies, including what we expect in 2011."
Amarin: AMR101 had positive data from its first pivotal trial in patients with very triglycerides.
Amicus: Amigal for Fabry disease is in a pivotal Phase 3 trial set to yield top-line data in H2/11.
Dendreon is a Best Idea based on blockbuster sales potential for prostate cancer immunotherapy Provenge, fueled in the near term by continued manufacturing and commercial expansion as well as upcoming announcement of a European launch strategy.
NPS Pharmaceuticals is a Best Idea based on 2011 expectations of highly compelling Phase 3 data read-out for previously-validated GATTEX in short bowel syndrome as well as hormone replacement drug NPSP558 in secondary hypoparathyroidism.
Orexigen: Contrave for obesity recently received a positive FDA panel recommendation that we think paves the way for approval in 2011.
Pharmasset: Hepatitis C nuc polymerase inhibitors will be key components of future therapy, in our view. We expect key events in 2011, including: Phase 2b data and a Phase 3 start for Roche-partnered RG7128, Phase2b data for wholly owned PSI-7977, and data from Pharmasset’s proprietary all oral, two-nuc combination study of PSI-938 and PSI-7977.
Amarin closed Tuesday at $5.92, up $0.12, or 2.07 percent. Amicus closed at $4.01, up $0.03, or 0.75 percent. Dendreon ended at $36.28, down $0.28, or 0.77 percent. NPS Pharmaceuticals closed at $7.11, up $0.09, or 1.28 percent. Orexigen closed at $9.01, down $0.01, or 0.11 percent. Pharmasset was up to $47.19, gaining $0.42, or 0.90 percent.
Canaccord said, "We believe that small and mid-cap biotech stock performance will continue to be driven by key catalysts: late-stage clinical data, FDA decisions, and sales growth. In addition to profiling each of our Best Ideas, we are providing quick updates on many of our coverage companies, including what we expect in 2011."
Amarin: AMR101 had positive data from its first pivotal trial in patients with very triglycerides.
Amicus: Amigal for Fabry disease is in a pivotal Phase 3 trial set to yield top-line data in H2/11.
Dendreon is a Best Idea based on blockbuster sales potential for prostate cancer immunotherapy Provenge, fueled in the near term by continued manufacturing and commercial expansion as well as upcoming announcement of a European launch strategy.
NPS Pharmaceuticals is a Best Idea based on 2011 expectations of highly compelling Phase 3 data read-out for previously-validated GATTEX in short bowel syndrome as well as hormone replacement drug NPSP558 in secondary hypoparathyroidism.
Orexigen: Contrave for obesity recently received a positive FDA panel recommendation that we think paves the way for approval in 2011.
Pharmasset: Hepatitis C nuc polymerase inhibitors will be key components of future therapy, in our view. We expect key events in 2011, including: Phase 2b data and a Phase 3 start for Roche-partnered RG7128, Phase2b data for wholly owned PSI-7977, and data from Pharmasset’s proprietary all oral, two-nuc combination study of PSI-938 and PSI-7977.
Amarin closed Tuesday at $5.92, up $0.12, or 2.07 percent. Amicus closed at $4.01, up $0.03, or 0.75 percent. Dendreon ended at $36.28, down $0.28, or 0.77 percent. NPS Pharmaceuticals closed at $7.11, up $0.09, or 1.28 percent. Orexigen closed at $9.01, down $0.01, or 0.11 percent. Pharmasset was up to $47.19, gaining $0.42, or 0.90 percent.
Friday, November 19, 2010
Dendreon (Nasdaq:DNDN) Shares Soar on MEDCAC Panel Support
A positive review from the MEDCAC panel on the effectiveness of its cancer drug Provenge caused the share price of Dendreon (Nasdaq:DNDN) to soar by almost 7 percent by the close of Thursday's trading session.
This is good news for Dendreon, but the market will wait until March when Medicare officials will make a final decision on whether or not to cover the drug or not.
With most diagnosed with prostrate cancer being senior men, which Medicare primarily covers, it is essential to the success of the drug that is is approved by Medicare, or for the most part, it'll be irrelevant to the company.
Although some view this as a nod toward assured approval, that's not necessarily a certainty, as the drug costs $93,000 per each patient, while extending their live on average, only four months.
Even so, it does seem to at least increase the probability of the chance of it being approved, and that is a good step at this time.
Dendreon closed Thursday at $38.23, rising by $2.36, or 6.58 percent. Volume was over three times the 3-month daily average.
This is good news for Dendreon, but the market will wait until March when Medicare officials will make a final decision on whether or not to cover the drug or not.
With most diagnosed with prostrate cancer being senior men, which Medicare primarily covers, it is essential to the success of the drug that is is approved by Medicare, or for the most part, it'll be irrelevant to the company.
Although some view this as a nod toward assured approval, that's not necessarily a certainty, as the drug costs $93,000 per each patient, while extending their live on average, only four months.
Even so, it does seem to at least increase the probability of the chance of it being approved, and that is a good step at this time.
Dendreon closed Thursday at $38.23, rising by $2.36, or 6.58 percent. Volume was over three times the 3-month daily average.
Subscribe to:
Posts (Atom)